[NSAIDs] Non-steroidal anti-inflammatory drugs consider an important group of drugs due to their properties as anti-inflammatory and it have both antipyretic and pain killer activities. [COX-II] plays an important role all over oncogenesis and here we attempt the same thing to search the use of [NSAID] (Etodolac & tolmetin) in conjugation with current cytotoxic agent (Gemcitabine) for the prevention and/or management of cancer. This study distinguishes the designing and synthesis of mutual prodrug of [NSAID] & gemcitabine, which is specified to create the concomitantly pharmacological action as a one chemical entity with amend of targeting of drug. The synthesized compound was conferred by TLC, CHNS, FTIR and physicochemical properties. The newly synthesized prodrug is predicted to reduce the adverse effects of [NSAIDs] on the (GIT) gastrointestinal tract with enhancement of gemcitabine oral bioavailability and its targeting.
Etodolac, tolmetin, gemcitabine, drug targeting, mutual prodrug.